Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.78
-0.09 (-0.70%)
At close: Jun 8, 2026, 4:00 PM EDT
12.69
-0.09 (-0.70%)
After-hours: Jun 8, 2026, 7:28 PM EDT
Generate Biomedicines Revenue
Generate Biomedicines had revenue of $7.22M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $30.30M. In the year 2025, Generate Biomedicines had annual revenue of $31.89M with 55.89% growth.
Revenue (ttm)
$30.30M
Revenue Growth
+55.89%
P/S Ratio
54.07
Revenue / Employee
$97,112
Employees
312
Market Cap
1.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.89M | 11.43M | 55.89% |
| Dec 31, 2024 | 20.46M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGENB News
- 11 days ago - Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - PRNewsWire
- 25 days ago - Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley - TheFly
- 4 weeks ago - Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright - TheFly
- 4 weeks ago - Generate Biomedicines Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Generate Biomedicines Earnings release: Q1 2026 - Filings
- 4 weeks ago - Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M - TheFly
- 4 weeks ago - Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update - PRNewsWire
- 2 months ago - Generate Biomedicines initiated with a Buy at H.C. Wainwright - TheFly